NO20082073L - Anti-myostatin-antistoffer - Google Patents

Anti-myostatin-antistoffer

Info

Publication number
NO20082073L
NO20082073L NO20082073A NO20082073A NO20082073L NO 20082073 L NO20082073 L NO 20082073L NO 20082073 A NO20082073 A NO 20082073A NO 20082073 A NO20082073 A NO 20082073A NO 20082073 L NO20082073 L NO 20082073L
Authority
NO
Norway
Prior art keywords
antibodies
gdf
bind
myostatin antibodies
increasing
Prior art date
Application number
NO20082073A
Other languages
English (en)
Norwegian (no)
Inventor
Rosamund Carol Smith
Bomie Han
Andrew Korytko
Pamela Jean Mitchell
Linda O'bryan
Rong Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20082073L publication Critical patent/NO20082073L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20082073A 2005-10-06 2008-05-02 Anti-myostatin-antistoffer NO20082073L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72467005P 2005-10-06 2005-10-06
US72523505P 2005-10-11 2005-10-11
US72606205P 2005-10-12 2005-10-12
PCT/US2006/038818 WO2007044411A2 (fr) 2005-10-06 2006-10-05 Anticorps anti-myostatine

Publications (1)

Publication Number Publication Date
NO20082073L true NO20082073L (no) 2008-06-17

Family

ID=37943347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082073A NO20082073L (no) 2005-10-06 2008-05-02 Anti-myostatin-antistoffer

Country Status (13)

Country Link
US (2) US7635760B2 (fr)
EP (1) EP1951756B1 (fr)
JP (1) JP5052517B2 (fr)
KR (1) KR101135220B1 (fr)
CN (1) CN101277976B (fr)
AU (1) AU2006302494B2 (fr)
BR (1) BRPI0616923A2 (fr)
CA (1) CA2624976A1 (fr)
EA (1) EA015589B1 (fr)
ES (1) ES2533464T3 (fr)
IL (1) IL189579A0 (fr)
NO (1) NO20082073L (fr)
WO (1) WO2007044411A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635760B2 (en) * 2005-10-06 2009-12-22 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2007114319A1 (fr) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Procédé de régulation de la cinétique sanguine d'un anticorps
KR101123531B1 (ko) * 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
ES2477567T3 (es) 2007-06-01 2014-07-17 Wyeth Llc Tratamiento de leucemia resistente a imatinib usando 4-aminoquinolin-3-carbonitrilos
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
AU2009288354A1 (en) * 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
WO2012024242A1 (fr) * 2010-08-16 2012-02-23 Amgen Inc. Anticorps se liant à la myostatine, compositions et procédés
AR082641A1 (es) 2010-09-07 2012-12-19 Imclone Llc Composiciones de anticuerpo anti-vegfr-3
EP2647706B1 (fr) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène, apte à se lier de façon répétée à une pluralité de molécules d'antigène
CN102212545B (zh) * 2011-04-07 2013-05-08 北京济福霖生物技术有限公司 利用锌指核酸酶敲除牛β-乳球蛋白基因的方法
CN102260711B (zh) * 2011-06-24 2013-09-18 北京济福霖生物技术有限公司 利用锌指核酸酶敲除牛肌肉抑制素基因的方法
EP2780368B1 (fr) 2011-11-14 2018-01-03 Regeneron Pharmaceuticals, Inc. Compositions et méthodes permettant d'augmenter la masse et la force musculaires par un effet antagoniste spécifiquement dirigé contre la myostatine et/ou l'activine a
CN102660577B (zh) * 2012-04-18 2013-12-25 山东省农业科学院奶牛研究中心 利用锌指核酸酶敲除牛整合素β6亚基基因的方法
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
DK3835310T3 (da) 2012-09-13 2024-06-03 Bristol Myers Squibb Co Fibronektinbaserede skeletdomæneproteiner, der binder til myostatin
WO2014119634A1 (fr) * 2013-01-30 2014-08-07 独立行政法人国立精神・神経医療研究センター Agent de formation musculaire et composition pharmaceutique le contenant
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
PT2981822T (pt) * 2013-05-06 2020-12-07 Scholar Rock Inc Composições e métodos para modulação do fator de crescimento
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
EP3119432B1 (fr) * 2014-03-19 2020-01-08 MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital Anticorps contre des glycopeptides immunogènes, composition les comprenant et son utilisation
EP2960653A1 (fr) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Trousse de diagnostic et procédé pour l'identification de la manipulation de la masse musculaire chez un animal domestique
US10307480B2 (en) 2014-11-06 2019-06-04 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CA2982810A1 (fr) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methode pour augmenter la resistance et la fonctionnalite avec des inhibiteurs de gdf-8
EP3350220B1 (fr) 2015-09-15 2021-05-19 Scholar Rock, Inc. Anticorps anti-pro-myostatine/myostatine latente et leurs utilisations
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20180094110A (ko) 2016-01-08 2018-08-22 스칼러 락, 인크. 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
SI3565592T1 (sl) 2017-01-06 2023-05-31 Scholar Rock, Inc. Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina
US11693013B2 (en) * 2017-03-10 2023-07-04 UCL Business Ltd. Method relating to myostatin pathway inhibition
EP3758800A1 (fr) 2018-03-01 2021-01-06 Regeneron Pharmaceuticals, Inc. Procédés de modification de composition corporelle
CN113195532A (zh) 2018-12-18 2021-07-30 瑞泽恩制药公司 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
WO2024064842A1 (fr) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de l'obésité, du diabète et de la dysfonction hépatique

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
DE69432815T2 (de) 1993-03-19 2003-12-11 The Johns Hopkins University School Of Medicine, Baltimore Wachstumsfaktor-8
KR100227406B1 (ko) * 1993-05-12 1999-12-01 브루스 엠. 에이센 Bmp-11 조성물
DK0776337T3 (da) 1994-07-08 2005-12-12 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-11
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
WO1999006559A1 (fr) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Procedes d'identification des recepteurs des facteurs de differenciation de la croissance
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO1999024057A2 (fr) 1997-11-07 1999-05-20 Genetics Inst Utilisations neuronales de bmp-11
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
CA2319703C (fr) 1998-02-05 2005-09-20 The Johns Hopkins University School Of Medicine Facteur-8 de differenciation de la croissance
DE69941116D1 (de) 1998-05-06 2009-08-27 Metamorphix Inc G von gdf-8
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US20040138118A1 (en) 2002-09-16 2004-07-15 Neil Wolfman Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
SI1581649T1 (sl) * 2002-12-20 2011-09-30 Amgen Inc Vezna sredstva, ki zavirajo miostatin
CN1829532A (zh) 2003-06-02 2006-09-06 惠氏公司 肌肉抑制素（gdf8）抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
NZ529860A (en) * 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
RU2422460C2 (ru) * 2003-12-31 2011-06-27 Шеринг-Плоу Лтд. Выделенный пептид, обладающий специфической связывающей анти-gdf-8 антитело активностью, выделенная молекула нуклеиновой кислоты, вектор экспрессии, клетка-хозяин, способ получения пептида, вакцинная композиция и способ вызывания иммунного ответа анти-gdf-8, способ скрининга для отбора анти-gdf-8 антитела и способ понижающего регулирования активности gdf-8 у животного
WO2005094446A2 (fr) * 2004-03-23 2005-10-13 Eli Lilly And Company Anticorps diriges contre la myostatine
AU2005272646A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
MX2007011400A (es) * 2005-03-23 2007-10-11 Wyeth Corp Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
AU2006239860B2 (en) 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
US20090215671A1 (en) * 2005-05-27 2009-08-27 The Regents Of The University Of California Compositions And Methods For Treatment of Neural Disorders Using Transforming Growth Factor-Beta Superfamily Proteins And Their Antagonists
ES2659114T3 (es) * 2005-08-19 2018-03-13 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y usos en el tratamiento de ALS y otros trastornos asociados con GDF-8
US7635760B2 (en) 2005-10-06 2009-12-22 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US20070149458A1 (en) 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
KR101123531B1 (ko) 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途

Also Published As

Publication number Publication date
US20100087631A1 (en) 2010-04-08
EP1951756A2 (fr) 2008-08-06
JP2009511480A (ja) 2009-03-19
IL189579A0 (en) 2008-08-07
US7745583B2 (en) 2010-06-29
CN101277976A (zh) 2008-10-01
US20080299126A1 (en) 2008-12-04
BRPI0616923A2 (pt) 2011-07-05
US7635760B2 (en) 2009-12-22
AU2006302494A1 (en) 2007-04-19
CA2624976A1 (fr) 2007-04-19
KR20080045733A (ko) 2008-05-23
ES2533464T3 (es) 2015-04-10
JP5052517B2 (ja) 2012-10-17
EA015589B1 (ru) 2011-10-31
KR101135220B1 (ko) 2012-04-24
EP1951756B1 (fr) 2015-01-07
WO2007044411A3 (fr) 2007-08-16
CN101277976B (zh) 2012-04-11
EA200801027A1 (ru) 2008-10-30
AU2006302494B2 (en) 2011-01-06
WO2007044411A2 (fr) 2007-04-19

Similar Documents

Publication Publication Date Title
NO20082073L (no) Anti-myostatin-antistoffer
WO2008030706A3 (fr) Anticorps anti-myostatine
ATE557042T1 (de) Anti-myostatin-antikörper
WO2007047112A3 (fr) Anticorps anti-myostatine
EA200970874A1 (ru) Антитела против склеростина
NO20082905L (no) Anti-IL-17 antistoff
MX2022000112A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
EP2400021A3 (fr) Procédés de type ErbB3 et compositions pour traiter des tumeurs malignes
WO2016081746A8 (fr) Anticorps comprenant des régions constantes de chaîne lourde modifiées
EA201000471A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
NO20083793L (no) Antistoffer mot amyloid-beta peptid
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
PH12013500858B1 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments that specifically bind cd 154 and uses thereof
PE20071055A1 (es) Anticuerpos anti mn
AR058983A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
JP2017502023A5 (fr)
MX2022007791A (es) Partes de unión a claudin18.2 y usos de estas.
EP4276108A3 (fr) Méthodes de traitement de maladies dans lesquelles l'activité de l'il-13 est préjudiciable à l'aide d'anticorps anti-il-13
MX2023006969A (es) Moleculas de union a gucy2c y sus usos.
MX2022003523A (es) Proteinas de union a antigenos.
CY1115979T1 (el) Αντισωματα κατα της μυοστατινης
CY1113928T1 (el) Αντισωματα αντι-μυοστατινης
WO2021231803A3 (fr) Molécules de liaison pour le traitement de la covid-19

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application